NVO Competition Analysis

Novo Nordisk A/S Peer Comparison

Metric	Value	Ranking
Market Cap	$273.0 Billion	1/21	NVO $273.0B	VRTX $125.9B	REGN $62.9B	SGEN $43.2B	ALNY $31.5B	BNTX $27.6B	BMRN $11.9B	MRNA $10.2B	MDGL $6.8B	RETA $6.6B	TGTX $6.2B	SRPT $5.8B	CRSP $3.3B	NVAX $1.2B	NTLA $837.5M	ICPT $794.7M	CVAC $713.7M	DNA $441.1M	TERN $251.4M	HEPA $3.1M	CWBR $1.2M
Gross Margin	85%	9/21	ICPT 100%	NTLA 100%	CRSP 100%	MDGL 97%	RETA 96%	CVAC 96%	REGN 93%	TGTX 86%	NVO 85%	VRTX 85%	ALNY 83%	BMRN 82%	SRPT 80%	BNTX 80%	DNA 78%	SGEN 75%	NVAX 58%	MRNA 23%	CWBR 0%	HEPA 0%	TERN 0%
Profit Margin	33%	3/21	RETA 100%	CVAC 68%	NVO 33%	VRTX 31%	REGN 24%	SRPT 24%	TGTX 22%	BNTX 22%	BMRN 17%	CWBR 0%	HEPA 0%	TERN 0%	ICPT -3%	ALNY -14%	SGEN -33%	MDGL -58%	NVAX -92%	NTLA -100%	CRSP -100%	MRNA -100%	DNA -100%
EBITDA margin	47%	2/21	CVAC 76%	NVO 47%	VRTX 41%	BNTX 39%	TGTX 30%	REGN 26%	SRPT 25%	BMRN 22%	ICPT -3%	ALNY -26%	SGEN -34%	MDGL -54%	NVAX -61%	CWBR -100%	HEPA -100%	TERN -100%	MRNA -129%	CRSP -171%	DNA -327%	RETA -356%	NTLA -1040%
Quarterly Revenue	$12.6 Billion	1/21	NVO $12.6B	REGN $3.8B	VRTX $2.9B	BNTX $1.3B	MRNA $966.0M	BMRN $747.3M	SRPT $658.4M	SGEN $648.7M	ALNY $593.2M	CVAC $542.7M	TGTX $108.2M	MDGL $103.3M	ICPT $88.8M	NVAX $88.3M	DNA $43.8M	CRSP $35.0M	RETA $22.7M	NTLA $12.9M	CWBR $0	HEPA $0	TERN $0
Quarterly Earnings	$4.2 Billion	1/21	NVO $4.2B	REGN $917.7M	VRTX $913.0M	CVAC $371.5M	BNTX $285.2M	RETA $193.0M	SRPT $159.0M	BMRN $124.9M	TGTX $23.3M	ICPT -$2.8M	CWBR -$4.3M	HEPA -$4.9M	TERN -$21.8M	CRSP -$37.3M	MDGL -$59.4M	NVAX -$81.0M	ALNY -$83.8M	DNA -$107.5M	NTLA -$128.9M	SGEN -$215.8M	MRNA -$1.1B
Quarterly Free Cash Flow	-$627.9 Billion	18/21	VRTX $492.0M	CVAC $385.5M	SRPT $54.0M	ICPT $3.9M	CWBR -$1.8M	HEPA -$2.5M	TERN -$14.6M	TGTX -$25.7M	CRSP -$50.3M	DNA -$56.1M	RETA -$70.2M	SGEN -$79.8M	NTLA -$86.2M	ALNY -$103.8M	MDGL -$104.7M	NVAX -$175.4M	BNTX -$609.2M	NVO -$627.9M	BMRN -$0	REGN -$0	MRNA -$0
Trailing 4 Quarters Revenue	$42.8 Billion	2/21	BMRN $736.0B	NVO $42.8B	REGN $14.2B	VRTX $11.0B	MRNA $3.2B	BNTX $3.0B	SGEN $2.3B	ALNY $2.2B	SRPT $1.9B	NVAX $682.2M	CVAC $596.5M	TGTX $329.0M	ICPT $317.7M	DNA $227.0M	MDGL $180.1M	NTLA $57.9M	CRSP $36.6M	RETA $24.4M	CWBR $0	HEPA $0	TERN $0
Trailing 4 Quarters Earnings	$14.9 Billion	2/21	NVO $12.6B	REGN $3.8B	VRTX $2.9B	BNTX $1.3B	MRNA $966.0M	BMRN $747.3M	SRPT $658.4M	SGEN $648.7M	ALNY $593.2M	CVAC $542.7M	TGTX $108.2M	MDGL $103.3M	ICPT $88.8M	NVAX $88.3M	DNA $43.8M	CRSP $35.0M	RETA $22.7M	NTLA $12.9M	CWBR -$0	HEPA -$0	TERN -$0
Quarterly Earnings Growth	29%	10/21	CVAC 794%	RETA 362%	TGTX 262%	SRPT 248%	NVAX 55%	HEPA 54%	DNA 49%	MDGL 47%	ALNY 39%	NVO 29%	NTLA 2%	TERN -4%	VRTX -6%	SGEN -13%	REGN -21%	BNTX -43%	CWBR -59%	BMRN -99%	ICPT -101%	CRSP -142%	MRNA -616%
Annual Earnings Growth	13%	10/21	BMRN 419%	SRPT 405%	CVAC 144%	RETA 72%	NVAX 67%	MRNA 67%	HEPA 57%	DNA 51%	TERN 19%	NVO 13%	REGN 5%	CWBR 1%	NTLA -4%	MDGL -14%	SGEN -26%	CRSP -48%	TGTX -93%	VRTX -113%	ICPT -124%	BNTX -171%	ALNY -191%
Quarterly Revenue Growth	30%	7/21	CVAC 2896%	RETA 2885%	NTLA 772%	TGTX 146%	SRPT 66%	ALNY 35%	NVO 30%	SGEN 27%	DNA 26%	VRTX 16%	ICPT 14%	REGN 10%	MDGL 0%	CWBR 0%	HEPA 0%	TERN 0%	BNTX -20%	MRNA -66%	NVAX -70%	CRSP -83%	BMRN -100%
Annual Revenue Growth	20%	6/21	CVAC 1284%	RETA 596%	NVAX 91%	NTLA 70%	SRPT 37%	NVO 20%	SGEN 15%	BMRN 14%	DNA 13%	VRTX 10%	ICPT 8%	REGN 5%	MDGL 0%	CWBR 0%	HEPA 0%	TERN 0%	ALNY -19%	BNTX -34%	TGTX -39%	MRNA -61%	CRSP -82%
Cash On Hand	$2.3 Billion	3/21	BNTX $10.7B	VRTX $4.6B	NVO $2.3B	MRNA $1.9B	SRPT $1.1B	ALNY $966.4M	BMRN $942.8M	CVAC $605.3M	DNA $561.6M	NVAX $530.2M	SGEN $428.6M	CRSP $298.3M	NTLA $189.2M	TGTX $179.9M	TERN $161.4M	ICPT $102.7M	MDGL $100.0M	RETA $48.8M	CWBR $6.2M	HEPA $1.5M	REGN -$0
Short Term Debt	$1.9 Billion	1/21	NVO $1.9B	VRTX $92.3M	BNTX $43.4M	ALNY $41.9M	NTLA $20.2M	CRSP $17.3M	NVAX $7.0M	CVAC $5.7M	RETA $2.5M	HEPA $2.2M	TGTX $1.2M	MDGL $983,000	TERN $428,000	BMRN -$0	REGN -$0	SRPT -$0	SGEN -$0	ICPT -$0	CWBR -$0	MRNA -$0	DNA -$0
Long Term Debt	$13.2 Billion	1/21	NVO $13.2B	REGN $2.0B	VRTX $1.7B	SRPT $1.3B	ALNY $1.3B	MRNA $710.0M	BMRN $595.1M	DNA $438.8M	TGTX $252.6M	BNTX $235.9M	ICPT $223.9M	NVAX $223.4M	CRSP $206.4M	NTLA $190.0M	RETA $163.5M	MDGL $118.6M	SGEN $113.5M	CVAC $38.3M	TERN $919,000	CWBR $0	HEPA $0
PE	18.33	3/21	TGTX 265.27	SRPT 24.54	NVO 18.33	REGN 14.25	CVAC 5.90	BMRN 0.11	NVAX -1.00	VRTX -1.00	ALNY -1.00	RETA -1.00	SGEN -1.00	ICPT -1.00	MDGL -1.00	NTLA -1.00	CRSP -1.00	CWBR -1.00	HEPA -1.00	MRNA -1.00	BNTX -1.00	TERN -1.00	DNA -1.00
PS	43.22	3/21	RETA 269.17	CRSP 90.70	NVO 43.22	MDGL 37.85	TGTX 18.85	SGEN 18.76	ALNY 14.52	NTLA 14.47	VRTX 11.44	BNTX 8.31	REGN 4.43	MRNA 3.16	SRPT 3.03	ICPT 2.50	DNA 1.94	NVAX 1.76	CVAC 1.09	BMRN 0.02	CWBR -1.00	HEPA -1.00	TERN -1.00
PB	12.90	5/21	ALNY 469.15	RETA 75.22	TGTX 27.89	SGEN 16.92	NVO 12.90	ICPT 11.06	MDGL 9.04	VRTX 7.68	SRPT 3.78	BMRN 2.10	REGN 1.80	CRSP 1.72	BNTX 1.29	NTLA 0.96	MRNA 0.94	CVAC 0.90	TERN 0.73	DNA 0.62	CWBR 0.13	NVAX 0.00	HEPA 0.00
PC	118.25	2/21	RETA 134.44	NVO 118.25	SGEN 100.70	MDGL 68.17	TGTX 34.48	ALNY 32.57	VRTX 27.56	BMRN 12.60	CRSP 11.14	ICPT 7.74	MRNA 5.31	SRPT 5.23	NTLA 4.43	BNTX 2.57	NVAX 2.27	HEPA 2.05	TERN 1.56	CVAC 1.18	DNA 0.79	CWBR 0.19	REGN -1.00
Liabilities to Equity	2.25	4/21	ALNY 62.20	RETA 4.76	ICPT 4.47	NVO 2.25	TGTX 1.60	SRPT 1.59	DNA 0.92	SGEN 0.42	MDGL 0.38	VRTX 0.37	NTLA 0.37	CWBR 0.32	MRNA 0.30	BMRN 0.24	CVAC 0.18	CRSP 0.16	BNTX 0.16	REGN 0.08	TERN 0.05	NVAX 0.00	HEPA 0.00
ROA	0.03	6/21	BMRN 1522%	CVAC 14%	REGN 12%	SRPT 6%	TGTX 4%	NVO 3%	VRTX -2%	BNTX -3%	ALNY -7%	NVAX -12%	ICPT -15%	RETA -16%	CRSP -16%	SGEN -21%	TERN -24%	MRNA -25%	DNA -40%	NTLA -44%	MDGL -45%	CWBR -99%	HEPA -611%
ROE	0.10	8/21	HEPA 5583%	BMRN 1881%	NVAX 30%	CVAC 17%	SRPT 15%	REGN 13%	TGTX 11%	NVO 10%	VRTX -3%	BNTX -4%	CRSP -19%	TERN -26%	SGEN -29%	MRNA -33%	NTLA -60%	MDGL -62%	DNA -76%	ICPT -82%	RETA -94%	CWBR -131%	ALNY -415%
Current Ratio	1.45	16/21	TERN 20.15	REGN 13.50	CRSP 7.23	BNTX 7.22	CVAC 6.60	BMRN 5.25	MRNA 4.36	CWBR 4.17	NTLA 3.73	VRTX 3.68	MDGL 3.62	SGEN 3.35	DNA 2.08	TGTX 1.63	SRPT 1.63	NVO 1.45	ICPT 1.22	RETA 1.21	ALNY 1.02	HEPA 0.90	NVAX 0.71
Quick Ratio	0.08	21/21	TGTX 265.27	SRPT 24.54	NVO 18.33	REGN 14.25	CVAC 5.90	BMRN 0.11	NVAX -1.00	VRTX -1.00	ALNY -1.00	RETA -1.00	SGEN -1.00	ICPT -1.00	MDGL -1.00	NTLA -1.00	CRSP -1.00	CWBR -1.00	HEPA -1.00	MRNA -1.00	BNTX -1.00	TERN -1.00	DNA -1.00
Long Term Debt to Equity	0.62	6/21	ALNY} 18.69	ICPT} 3.12	RETA} 1.87	TGTX} 1.14	SRPT} 0.87	NVO} 0.62	DNA} 0.61	NTLA} 0.22	MDGL} 0.16	BMRN} 0.11	CRSP} 0.11	VRTX} 0.10	MRNA} 0.07	REGN} 0.06	CVAC} 0.05	SGEN} 0.04	BNTX} 0.01	CWBR} 0.00	HEPA} 0.00	TERN} 0.00	NVAX} -0.36
Debt to Equity	0.72	6/21	ALNY 19.32	ICPT 3.12	RETA 1.90	TGTX 1.14	SRPT 0.87	NVO 0.72	DNA 0.61	NTLA 0.24	MDGL 0.16	CRSP 0.12	VRTX 0.11	BMRN 0.11	MRNA 0.07	REGN 0.06	CVAC 0.06	SGEN 0.04	BNTX 0.01	CWBR 0.00	TERN 0.00	NVAX -0.37	HEPA -5.47
Burn Rate	5.79	5/21	ICPT 8.75	TERN 7.36	ALNY 6.69	CRSP 5.98	NVO 5.79	NVAX 5.78	DNA 4.49	SGEN 1.95	MRNA 1.68	MDGL 1.55	CWBR 1.43	NTLA 1.34	HEPA 0.28	REGN 0.00	RETA -0.26	CVAC -1.49	VRTX -5.55	BMRN -9.32	SRPT -10.42	TGTX -13.90	BNTX -36.60
Cash to Cap	0.01	17/21	CWBR 5.20	DNA 1.27	CVAC 0.85	TERN 0.64	HEPA 0.49	NVAX 0.44	BNTX 0.39	NTLA 0.23	SRPT 0.19	MRNA 0.19	ICPT 0.13	CRSP 0.09	BMRN 0.08	VRTX 0.04	ALNY 0.03	TGTX 0.03	NVO 0.01	RETA 0.01	SGEN 0.01	MDGL 0.01	REGN 0.00
CCR	-0.15	14/21	NVAX 2.16	MDGL 1.76	CRSP 1.35	ALNY 1.24	CVAC 1.04	NTLA 0.67	TERN 0.67	VRTX 0.54	HEPA 0.52	DNA 0.52	CWBR 0.42	SGEN 0.37	SRPT 0.34	NVO -0.15	RETA -0.36	TGTX -1.10	ICPT -1.38	BNTX -2.14	BMRN	REGN	MRNA
EV to EBITDA	3.17	7/21	TGTX} 192.67	VRTX} 103.84	BMRN} 71.43	REGN} 65.50	BNTX} 44.85	SRPT} 37.10	NVO} 3.17	CVAC} 0.73	CWBR} -1.00	HEPA} -1.00	TERN} -1.00	DNA} -2.22	NTLA} -6.41	MRNA} -7.24	NVAX} -16.86	CRSP} -54.35	RETA} -82.50	MDGL} -123.08	SGEN} -191.83	ALNY} -205.20	ICPT} -331.82
EV to Revenue	2.97	12/21	RETA 273.97	CRSP 88.66	MDGL 37.96	TGTX 19.08	SGEN 18.62	NTLA 14.83	ALNY 14.67	VRTX 11.19	BNTX 6.89	REGN 4.57	SRPT 3.15	NVO 2.97	ICPT 2.88	MRNA 2.79	DNA 1.40	NVAX 1.32	CVAC 0.46	BMRN 0.02	CWBR -1.00	HEPA -1.00	TERN -1.00

Novo Nordisk A/S Peer Comparison

Cookies